Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CASI Pharmaceuticals Inc (CASI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CASI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -1.56% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.58M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 8395 | Beta 0.65 | 52 Weeks Range 2.04 - 7.67 | Updated Date 04/2/2025 |
52 Weeks Range 2.04 - 7.67 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -117.68% | Operating Margin (TTM) -240.11% |
Management Effectiveness
Return on Assets (TTM) -26.6% | Return on Equity (TTM) -85.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 30843420 | Price to Sales(TTM) 1.14 |
Enterprise Value 30843420 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 1.4 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 15461100 | Shares Floating 5948099 |
Shares Outstanding 15461100 | Shares Floating 5948099 | ||
Percent Insiders 47.92 | Percent Institutions 24.22 |
Analyst Ratings
Rating 4 | Target Price 10 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CASI Pharmaceuticals Inc
Company Overview
History and Background
CASI Pharmaceuticals Inc. was founded in 1991. Initially focused on specialty pharmaceuticals in China, it has shifted its focus to developing and commercializing innovative therapeutics and pharmaceutical products across a broad spectrum of areas including hematology-oncology.
Core Business Areas
- Hematology-Oncology: Focuses on the development and commercialization of pharmaceutical products for the treatment of hematological malignancies and solid tumors.
Leadership and Structure
Wei-Wu He, Ph.D., is the Chairman and CEO. The company operates with a structure common for biotechnology companies, consisting of R&D, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- EVOMELA (melphalan for injection): An intravenous formulation of melphalan used as a high-dose conditioning treatment prior to stem cell transplantation in patients with multiple myeloma. Market share data is unavailable. Competitors include generics such as melphalan.
- MARQIBO (vincristine sulfate liposome injection): A sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate used to treat adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL). Market share data unavailable. Competitors include generic vincristine.
- CNCT19 (CIDR-101/oclacitinib):: An anti-CD19 chimeric antigen receptor (CAR)-T cell therapy being developed in China to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Market share data unavailable. Competitors include autologous anti-CD19 CAR-T cell therapies such as Kymriah and Yescarta.
- BI-1206: A monoclonal antibody designed to block CD47 which is being developed for the treatment of advanced hematologic malignancies and solid tumors. Market share data unavailable. Competitors include magrolimab.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The market for oncology drugs is rapidly growing, driven by an aging population and advancements in personalized medicine.
Positioning
CASI Pharmaceuticals is positioned as a specialty pharmaceutical company focused on bringing innovative oncology products to market, particularly in China and the US. Their strategy involves both developing proprietary products and licensing or acquiring promising candidates.
Total Addressable Market (TAM)
The global oncology drugs market is expected to reach hundreds of billions of dollars. CASI is positioned to capture a portion of this TAM with its portfolio of oncology-focused therapeutics. Specific TAM is difficult to define due to drug approval specifics, indications and global rollout.
Upturn SWOT Analysis
Strengths
- Focus on oncology therapeutics
- Strategic partnerships for product development and commercialization
- Experienced management team
- Access to the Chinese pharmaceutical market
- Portfolio of approved and pipeline products
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on partnerships for revenue generation
- Dependence on regulatory approvals for product commercialization
- Geographical concentration of operations
Opportunities
- Expanding product portfolio through strategic acquisitions and licensing deals
- Entering new geographical markets
- Developing innovative therapies targeting unmet medical needs in oncology
- Leveraging the growing demand for oncology drugs in China
- Capitalizing on advancements in personalized medicine and targeted therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays in product approvals
- Pricing pressures and reimbursement challenges
- Intellectual property infringement
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- JAZZ (JAZZ)
- MRTX (MRTX)
- ARVN (ARVN)
Competitive Landscape
CASI faces strong competition from larger pharmaceutical companies with greater resources and established market positions. CASI differentiates itself through a focus on niche oncology markets and strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on revenue and product sales, which are not available in this context.
Future Projections: Future growth projections are dependent on market conditions, drug approvals, and commercialization efforts, which are subject to change.
Recent Initiatives: Recent initiatives are centered on progressing clinical development programs, securing regulatory approvals for new products, and expanding commercial operations.
Summary
CASI Pharmaceuticals is a small company with a focus on oncology, leveraging partnerships to develop and commercialize its products, particularly in China. While it has a promising pipeline, its financial resources are limited and it faces significant competition. Approval of lead products is important to drive revenues. CASI needs to successfully navigate the regulatory landscape to ensure commercial success of its portfolio.
Similar Companies
ARVN
Arvinas Inc
ARVN
Arvinas Inc
JAZZ
Jazz Pharmaceuticals PLC
JAZZ
Jazz Pharmaceuticals PLC
KPTI
Karyopharm Therapeutics Inc
KPTI
Karyopharm Therapeutics Inc
VIRX
Viracta Therapeutics Inc
VIRX
Viracta Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CASI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-11 | Chairman & CEO Dr. Wei-Wu He Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.